Adcentrx Therapeutics Inc.
United States
4 articles with Adcentrx Therapeutics Inc.
-
Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.
-
The three-year agreement leverages AvantGen's yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.
-
Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates
2/14/2022
Adcentrx Therapeutics ("Adcentrx"), and AvantGen, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.
-
Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development
4/28/2021
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, announced the closing of $50m Series A financing to power the development of next generation ADC for improving patient treatment options.